Editas Medicine(US:EDIT)2025-11-10 12:06Financial Performance - Editas Medicine reported a net loss of $25.1 million, or $0.28 per share, for Q3 2025, a significant improvement from a net loss of $62.1 million, or $0.75 per share, in Q3 2024[10]. - Total operating expenses for Q3 2025 were $32.1 million, down from $65.7 million in Q3 2024[15]. - Editas Medicine reported total stockholders' equity of $13.5 million as of September 30, 2025, compared to $134.3 million at the end of 2024[17]. Revenue and Funding - Collaboration and other research and development revenues increased to $7.5 million in Q3 2025, compared to $0.1 million in Q3 2024, primarily due to milestone recognition under a collaboration agreement with BMS[10]. - Editas Medicine raised $17.8 million in gross equity proceeds from its ATM facility during Q3 2025[7]. Research and Development - Research and development expenses decreased by $27.9 million to $19.8 million in Q3 2025, down from $47.6 million in Q3 2024, mainly due to reduced clinical and manufacturing costs[10]. - The company plans to submit an IND/CTA for EDIT-401 by mid-2026 and aims to achieve initial human proof-of-concept data by the end of 2026[2][5]. - Preclinical data presented showed over 90% LDL-C reduction in non-human primates within 48 hours of a single dose of EDIT-401[5]. - The ≥90% reduction in LDL-C was achieved with a ≥6-fold mean increase in LDLR protein in the liver, requiring only moderate functional editing of LDLR alleles (10-40%) in the liver[5]. Cash Position - Editas Medicine extended its cash runway into Q3 2027, with cash, cash equivalents, and marketable securities totaling $165.6 million as of September 30, 2025, down from $269.9 million at the end of 2024[7][17].